UK Aid funding for Nottingham research to develop Zika virus vaccine miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Coronavirus vaccine developed in Nottingham to be tested on humans this year
Scientists from both universities are working together on developing a DNA vaccine against Covid-19
Updated
Medical staff and volunteers during a mass Covid-19 vaccination (Image: Yui Mok/PA Wire)
Never miss another Nottinghamshire story by signing up to our free email updatesInvalid EmailSomething went wrong, please try again later.
Subscribe
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplains more about how we use your data, and your rights. You can unsubscribe at any time.
Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide
February 04, 2021 11:35 ET | Source: Alphageneron Pharmaceuticals Alphageneron Pharmaceuticals Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) Alphageneron Pharmaceuticals, Inc., (Alphageneron) signed an Exclusive License Agreement with Multimmune GmbH, of Munich, Germany, (Multimmune) on October 1
st, 2020, for its clinical stage autologous Natural Killer (“NK”) cell therapy and companion diagnostic platform, for all fields worldwide.
The autologous NK cell therapy redirects a patient’s NK cells to target a cell membrane form of Heat Shock Protein 70 (Hsp70) which has been discovered to be highly expressed on many cancer cells, but not on healthy cells. NK cells are harvested from the patient’s blood, activated
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For .
Alphageneron PharmaceuticalsFebruary 4, 2021 GMT
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) Alphageneron Pharmaceuticals, Inc., (Alphageneron) signed an Exclusive License Agreement with Multimmune GmbH, of Munich, Germany, (Multimmune) on October 1st, 2020, for its clinical stage autologous Natural Killer (“NK”) cell therapy and companion diagnostic platform, for all fields worldwide.
The autologous NK cell therapy redirects a patient’s NK cells to target a cell membrane form of Heat Shock Protein 70 (Hsp70) which has been discovered to be highly expressed on many cancer cells, but not on healthy cells. NK cells are harvested from the patient’s blood, activated